Delmer Dee Raibourn III
@Avidity Partners Management Lp
Latest period2024 - Q3ReportedManaged Assets$1.96BTotal holdings81
Assets growth rate-16.7%Assets growth rate (2-Q avg)-20.41%Continuous growth in asset value0 quarters
Portfolio positions
This chart displays the top 10 holdings in Avidity Partners Management Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 81 positions.
Assets under management
The assets under management (AUM) of Avidity Partners Management Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 0 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 1.96B in assets, with a quarterly growth rate of -16.7% and a 2-quarter average growth rate of -20.41%. The portfolio is managed by Delmer Dee Raibourn III, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
CGONCg Oncology Inc
| 3.19% | $62.481M 1.656M shares@ $37.73 avg price | Increased 27.76% |
CATXPerspective Therapeutics Inc
| 2.35% | $45.977M 3.444M shares@ $13.36 avg price | Increased 13.38% |
GKOSGlaukos Corp
| 2.3% | $44.934M 344,900 shares@ $130.28 avg price | Increased 53.98% |
IDYAIdeaya Biosciences Inc
| 2.22% | $43.497M 1.373M shares@ $31.68 avg price | Increased 22.92% |
INSMInsmed Inc
| 2.21% | $43.216M 592,000 shares@ $73.0 avg price | Increased 37.68% |
EXASExact Sciences Corp
| 2.05% | $40.055M 588,000 shares@ $68.12 avg price | Increased 73.71% |
RVMDRevolution Medicines Inc
| 1.83% | $35.827M 790,000 shares@ $45.35 avg price | Increased 4.64% |
PHATPhathom Pharmaceuticals Inc
| 1.67% | $32.625M 1.804M shares@ $18.08 avg price | Increased 11.39% |
XENEXenon Pharmaceuticals Inc
| 1.65% | $32.205M 818,000 shares@ $39.37 avg price | Increased 8.49% |
BHVNBiohaven Ltd
| 1.19% | $23.236M 465,000 shares@ $49.97 avg price | Increased 3.34% |